

Cloprostenol Formulation

Version 4.6 Revision Date: 26.09.2023 SDS Number: 25274-00018 Date of last issue: 20.03.2023
Date of first issue: 24.10.2014

SECTION 1: IDENTIFICATION

Product name : Cloprostenol Formulation

Manufacturer or supplier's details

Company : MSD

Address : 91-105 Harpin Street
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--|------------|-----------------------|
| Benzyl alcohol | 100-51-6 | < 10 |
| Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate | 55028-72-3 | < 0.3 |

SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

Cloprostamol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

| | | |
|---|---|---|
| In case of skin contact | : | Wash with water and soap as a precaution. Get medical attention if symptoms occur. |
| In case of eye contact | : | Flush eyes with water as a precaution. Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : | None known. |
| Protection of first-aiders | : | No special precautions are necessary for first aid responders. |
| Notes to physician | : | Treat symptomatically and supportively. |

SECTION 5. FIREFIGHTING MEASURES

| | | |
|---|---|---|
| Suitable extinguishing media | : | Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire-fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for firefighters | : | Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment. |

SECTION 6. ACCIDENTAL RELEASE MEASURES

| | | |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : | Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can |

Cloprostenol Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 4.6 | Revision Date: 26.09.2023 | SDS Number: 25274-00018 | Date of last issue: 20.03.2023 Date of first issue: 24.10.2014 |
|----------------|------------------------------|----------------------------|---|

be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | : | Keep in properly labelled containers. Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types: Strong oxidizing agents |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|---|------------|----------------------------------|--|----------|
| Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)- 7-[2-[4-(3-chlorophenoxy)-3- hydroxybut-1-enyl]-3,5- dihydroxycyclopentyl]hept-5- enoate | 55028-72-3 | TWA | 0.01 ug/m ³ (OEB 5) | Internal |
| Further information: RSEN, Skin | | | | |
| | | Wipe limit | 0.1 ug/100 cm ² | Internal |

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

Engineering measures : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Colour : clear

Odour : No data available

Odour Threshold : No data available

pH : 5.6 - 6.1 (20 - 25 °C)

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

| | | |
|--|---|--|
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | No data available |
| Relative vapour density | : | No data available |
| Relative density | : | 1 |
| Density | : | No data available |
| Solubility(ies) | : | |
| Water solubility | : | soluble |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | : | |
| Viscosity, kinematic | : | No data available |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |
| Particle size | : | Not applicable |

SECTION 10. STABILITY AND REACTIVITY

| | | |
|------------------------------------|---|---|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | Can react with strong oxidizing agents. |
| Conditions to avoid | : | None known. |

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Components:**Benzyl alcohol:**

Acute oral toxicity : LD50 (Rat): 1,620 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 4.178 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Acute oral toxicity : LD50 (Rat): > 25 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): > 50 mg/kg
Application Route: Subcutaneous

LD50 (Rat): > 50 mg/kg
Application Route: Intramuscular

LD50 (Rat): 5 mg/kg
Application Route: Intravenous
Remarks: No mortality observed at this dose.

LD50 (Mouse): 350 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 54.7 mg/kg

Cloprostamol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

Application Route: Intravenous

TDLo (Monkey): 0.0025 - 0.025 mg/kg
Application Route: Intramuscular
Target Organs: Lungs
Symptoms: Diarrhoea, Vomiting, Rapid respiration

TDLo (Monkey): 0.0013 mg/kg
Application Route: Intramuscular
Target Organs: ovaries

Skin corrosion/irritation

Not classified based on available information.

Components:**Benzyl alcohol:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks : Not classified due to lack of data.
Can be absorbed through skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Benzyl alcohol:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks : Not classified due to lack of data.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

Components:**Benzyl alcohol:**

| | | |
|-----------------|---|-------------------------|
| Test Type | : | Maximisation Test |
| Exposure routes | : | Skin contact |
| Species | : | Guinea pig |
| Method | : | OECD Test Guideline 406 |
| Result | : | negative |

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

| | | |
|--------|---|------------|
| Result | : | Sensitiser |
|--------|---|------------|

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Benzyl alcohol:**

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| Genotoxicity in vivo | : | Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative |

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | | Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: negative |
| | | Test Type: Chromosomal aberration Test system: Human lymphocytes Result: equivocal |
| Genotoxicity in vivo | : | Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal Result: negative |

Cloprostamol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

Carcinogenicity

Not classified based on available information.

Components:**Benzyl alcohol:**

| | | |
|-------------------|---|-------------------------|
| Species | : | Mouse |
| Application Route | : | Ingestion |
| Exposure time | : | 103 weeks |
| Method | : | OECD Test Guideline 451 |
| Result | : | negative |

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α](+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Remarks : Not classified due to lack of data.

Reproductive toxicity

Not classified based on available information.

Components:**Benzyl alcohol:**

| | | |
|----------------------|---|---|
| Effects on fertility | : | Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials |
|----------------------|---|---|

| | | |
|-------------------------------|---|--|
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Mouse Application Route: Ingestion Result: negative |
|-------------------------------|---|--|

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α](+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

| | | |
|----------------------|---|--|
| Effects on fertility | : | Test Type: Three-generation study Species: Rat Application Route: Oral General Toxicity F1: NOAEL: 0.015 mg/kg body weight Fertility: NOAEL: > 0.04 mg/kg body weight Result: Animal testing did not show any effects on fertility. |
|----------------------|---|--|

| | | |
|--|---|---|
| | : | Species: Cattle Application Route: Intramuscular General Toxicity - Parent: LOAEL: 0.16 μ g/kg Result: positive Remarks: Abortion |
|--|---|---|

| | | |
|-------------------------------|---|--|
| Effects on foetal development | : | Test Type: Development Species: Rabbit Application Route: Subcutaneous |
|-------------------------------|---|--|

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

Teratogenicity: NOAEL: 0.250 µg/kg
Result: No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Oral
Teratogenicity: NOAEL: 100 µg/kg
Result: No teratogenic effects

Reproductive toxicity - Assessment : May damage fertility.

STOT - single exposure

Not classified based on available information.

Components:

Sodium [1α(Z),2β(1E,3R*),3α,5α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Target Organs : Lungs
Assessment : Causes damage to organs.

STOT - repeated exposure

Not classified based on available information.

Components:

Sodium [1α(Z),2β(1E,3R*),3α,5α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Target Organs : Ovary
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Benzyl alcohol:**

Species : Rat
NOAEL : 1.072 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 28 Days
Method : OECD Test Guideline 412

Sodium [1α(Z),2β(1E,3R*),3α,5α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Species : Rat
NOAEL : 0.05 mg/kg
LOAEL : 0.15 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Ovary

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

| | | |
|-------------------|---|--------------|
| Species | : | Rat |
| LOAEL | : | 0.0125 mg/kg |
| Application Route | : | Subcutaneous |
| Exposure time | : | 30 Days |
| Target Organs | : | Ovary |

| | | |
|-------------------|---|---------------|
| Species | : | Monkey |
| NOAEL | : | 0.05 mg/kg |
| LOAEL | : | 0.15 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 3 Months |
| Target Organs | : | Heart, Testis |

Aspiration toxicity

Not classified based on available information.

Components:

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

Not applicable

Experience with human exposure**Components:**

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:

| | | |
|---------------------|---|--|
| General Information | : | Target Organs: Uterus (including cervix) Symptoms: Embryo-foetal toxicity, foetal mortality, menstrual irregularities, miscarriage Target Organs: Lungs Symptoms: Asthma, bronchospasm |
| Inhalation | : | Target Organs: Lungs Symptoms: bronchospasm, Asthma Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust. Target Organs: Uterus (including cervix) Symptoms: Embryo-lethal effects, menstrual irregularities |
| Skin contact | : | Target Organs: Lungs Symptoms: bronchospasm Remarks: Can be absorbed through skin. Target Organs: Uterus (including cervix) Symptoms: Embryo-lethal effects |

Cloprostenol Formulation

Version 4.6 Revision Date: 26.09.2023 SDS Number: 25274-00018 Date of last issue: 20.03.2023
Date of first issue: 24.10.2014

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Benzyl alcohol:**

- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 460 mg/l
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 230 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 770 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 310 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 51 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Sodium [1 α (Z),2 β (1E,3R*),3 α ,5 α]-(+/-)-7-[2-[4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate:**Ecotoxicology Assessment**

- Acute aquatic toxicity : Toxic effects cannot be excluded
- Chronic aquatic toxicity : Toxic effects cannot be excluded

Persistence and degradability**Components:****Benzyl alcohol:**

- Biodegradability : Result: Readily biodegradable.
Biodegradation: 92 - 96 %
Exposure time: 14 d

Bioaccumulative potential**Components:****Benzyl alcohol:**

- Partition coefficient: n- : log Pow: 1.05

Cloprostenol Formulation

Version 4.6 Revision Date: 26.09.2023 SDS Number: 25274-00018 Date of last issue: 20.03.2023
Date of first issue: 24.10.2014

octanol/water

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

- Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
-

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

- UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

- UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

- UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

National Regulations**ADG**

| | | |
|----------------------|---|----------------|
| UN number | : | Not applicable |
| Proper shipping name | : | Not applicable |
| Class | : | Not applicable |
| Subsidiary risk | : | Not applicable |
| Packing group | : | Not applicable |
| Labels | : | Not applicable |
| Hazchem Code | : | Not applicable |

Special precautions for userNot applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

| | | |
|------------------------------------|---|---|
| Prohibition/Licensing Requirements | : | There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations. |
|------------------------------------|---|---|

The components of this product are reported in the following inventories:

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

| | | |
|---|---|---|
| Revision Date | : | 26.09.2023 |
| Sources of key data used to compile the Safety Data Sheet | : | Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/ |
| Date format | : | dd.mm.yyyy |

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with

Cloprostenol Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 4.6 | 26.09.2023 | 25274-00018 | Date of first issue: 24.10.2014 |

x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN